keyword
MENU ▼
Read by QxMD icon Read
search

Ferric carboxymaltose

keyword
https://www.readbyqxmd.com/read/29345426/single-dose-intravenous-iron-in-southeast-asian-heart-failure-patients-a-pilot-randomized-placebo-controlled-study-practice-asia-hf
#1
Tee Joo Yeo, Poh Shuan Daniel Yeo, Farid Abdul Hadi, Timothy Cushway, Kim Yee Lee, Fang Fang Yin, Anne Ching, Ruili Li, Seet Yoong Loh, Shir Lynn Lim, Raymond Ching-Chiew Wong, Bee Choo Tai, Arthur Mark Richards, Carolyn S P Lam
AIMS: Iron deficiency is highly prevalent in Southeast Asians with heart failure (HF) and associated with worse outcomes. This trial aimed to assess the effect of intravenous iron in Southeast Asians hospitalized with decompensated HF. METHODS AND RESULTS: Fifty patients hospitalized for acute decompensated HF, regardless of ejection fraction, with iron deficiency (defined as serum ferritin <300 ng/mL if transferrin saturation is <20%) were randomized to receive either one dose of intravenous ferric carboxymaltose (FCM) 1000 mg or placebo (0...
January 18, 2018: ESC Heart Failure
https://www.readbyqxmd.com/read/29338760/increased-plasmodium-chabaudi-malaria-mortality-in-mice-with-nutritional-iron-deficiency-can-be-reduced-by-short-term-adjunctive-iron-supplementation
#2
Filip C Castberg, Lasse Maretty, Trine Staalsoe, Casper Hempel, Erik Clasen-Linde, Lars Hviid, Jørgen A L Kurtzhals
BACKGROUND: Iron deficiency is the most widespread nutrient deficiency and an important cause of developmental impairment in children. However, some studies have indicated that iron deficiency can also protect against malaria, which is a leading cause of childhood morbidity and mortality in large parts of the world. This has rendered interventions against iron deficiency in malaria-endemic areas controversial. METHODS: The effect of nutritional iron deficiency on the clinical outcome of Plasmodium chabaudi AS infection in A/J mice and the impact of intravenous iron supplementation with ferric carboxymaltose were studied before and after parasite infection...
January 16, 2018: Malaria Journal
https://www.readbyqxmd.com/read/29304848/effectiveness-and-safety-of-ferric-carboxymaltose-compared-to-iron-sucrose-in-women-with-iron-deficiency-anemia-phase-iv-clinical-trials
#3
Amreen Naqash, Rifat Ara, Ghulam N Bader
BACKGROUND: Iron deficiency anemia (IDA) is a significant problem worldwide particularly in women. The aim of the study was to evaluate the effectiveness and safety of intravenous ferric carboxymaltose (FCM) in comparison to iron sucrose (IS) in women with IDA. METHOD: Two hundred patients at Department of Obstetrics and Gynaecology, Sher-i-Kashmir Institute of Medical Sciences Medical College and Hospital, Jammu & Kashmir, India identified with IDA were enrolled for the study...
January 5, 2018: BMC Women's Health
https://www.readbyqxmd.com/read/29298794/severe-fgf23-based-hypophosphataemic-osteomalacia-due-to-ferric-carboxymaltose-administration
#4
Klara Klein, Shonda Asaad, Michael Econs, Janet E Rubin
Ferric carboxymaltose (FCM) is a novel iron formulation increasingly prescribed due to its effectiveness and fast infusion time. FCM administration can cause an asymptomatic hypophosphataemia secondary to fibroblast growth factor 23 (FGF23) dysregulation. In patients with chronic iron needs, however, a severe, long-lasting hypophosphataemia can lead to osteomalacia with associated bone pain. Lack of awareness of this complication results in delayed time to diagnosis and significant morbidity. We report a case of a patient with Crohn's disease and chronic iron-deficiency anaemia receiving multiple doses of FCM who developed severe hypophosphataemic osteomalacia with urinary phosphate loss and increased FGF23...
January 3, 2018: BMJ Case Reports
https://www.readbyqxmd.com/read/29242729/altered-biodistribution-of-99mtc-dpd-on-bone-scan-after-intravenous-iron-supplement
#5
Eonwoo Shin, Minyoung Oh, Changhwan Sung, Ki-Hun Kim, Jin-Sook Ryu
We report a case with altered biodistribution of 99mTc-dicarboxypropane diphosphonate (99mTc-DPD) on whole body bone scan after intravenous iron supplement therapy. A 47-year-old male patient who had recently been detected with a hepatic mass suggestive of hepatocellular carcinoma underwent bone scan as staging work-up before surgery. Bone scan images at 3 h after injection of 99mTc-DPD demonstrated unusually increased blood pool activities in the heart, liver, and spleen with usual skeletal uptakes. The patient had been treated for severe anemia from hemorrhoid with two intravenous administration of ferric hydroxide carboxymaltose complex at approximately 22 h and 2 h prior to the 99mTc-DPD injection, which we consider as the most probable cause of altered biodistribution of 99mTc-DPD...
December 2017: Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/29238166/cardiovascular-liver-and-renal-toxicity-associated-with-an-intravenous-ferric-carboxymaltose-similar-versus-the-originator-compound
#6
Jorge E Toblli, Gabriel Cao, Luis Rico, Margarita Angerosa
Background: Ferric carboxymaltose (FCM) is a stable, non-dextran-based intravenous iron complex used to treat iron deficiency of various etiologies. As FCM is a nonbiological complex drug and cannot be fully characterized by physicochemical analyses, it is important to demonstrate in nonclinical models that FCM similars (FCMS) have similar biodistribution. Materials and methods: A total of 30 nonanemic rats were treated weekly with 40 mg iron/kg body weight intravenous FCM, FCMS, or isotonic saline (controls) for 4 weeks...
2017: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/29174251/effect-of-ferric-carboxymaltose-on-hospitalization-and-mortality-outcomes-in-chronic-heart-failure-a-meta-analysis
#7
Jamshed Dalal, Vijay Katekhaye, Rishi Jain
INTRODUCTION: Iron administration especially intravenous iron therapy is associated with improvements in exercise capacity and quality of life in patients with chronic heart failure (CHF). Our aim was to assess effect of ferric carboxymaltose (FCM) on hospitalization and mortality outcomes in CHF. MATERIALS AND METHODS: A literature search across PUBMED, Google Scholar and trials database www.clinicaltrials.gov was conducted to search for randomized controlled trials (till August 2016) comparing FCM to placebo in CHF with or without anaemia...
November 2017: Indian Heart Journal
https://www.readbyqxmd.com/read/29165637/a-controlled-study-of-the-effects-of-ferric-carboxymaltose-on-bone-and-haematinic-biomarkers-in-chronic-kidney-disease-and-pregnancy
#8
Louis L Huang, Darren Lee, Stefanie M Troster, Annette B Kent, Matthew A Roberts, Iain C Macdougall, Lawrence P McMahon
Background: Intravenous (IV) iron can modulate fibroblast growth factor 23 (FGF23) concentrations and cause transient but significant hypophosphataemia. However, it is unknown what other markers might be involved, especially in different patient groups. This study aimed to determine changes in bone and haematinic biomarkers following IV ferric carboxymaltose (FCM) and to identify risk factors for hypophosphataemia in pregnant subjects and those with chronic kidney disease (CKD). Methods: Changes in bone [serum FGF23, fractional excretion of phosphate urinary fractional excretion of phosphate (FEPi), serum phosphate and serum vitamin D derivatives] and haematinic [plasma hepcidin, serum ferritin and transferrin saturation (TSAT)] biomarkers after 1 g of IV FCM were followed in iron-deficient pregnant and CKD patients and compared with controls (estimated glomerular filtration rate > 60 mL/min/1...
November 17, 2017: Nephrology, Dialysis, Transplantation
https://www.readbyqxmd.com/read/29149437/a-blinded-randomized-placebo-controlled-study-to-investigate-the-efficacy-and-safety-of-ferric-carboxymaltose-in-iron-deficient-patients-with-fibromyalgia
#9
Chad S Boomershine, Todd A Koch, David Morris
INTRODUCTION: This study sought to compare efficacy and safety of ferric carboxymaltose vs. placebo in iron-deficient patients with fibromyalgia. METHODS: This blinded, placebo-controlled, phase 2 study randomized adults with fibromyalgia and Revised Fibromyalgia Impact Questionnaire (FIQR) scores ≥ 60, ferritin levels < 0.05 µg/ml, and transferrin saturation < 20% (1:1) to receive ferric carboxymaltose [15 mg/kg (up to 750 mg)], or placebo (15 cc normal saline) intravenously on study days 0 and 5...
November 17, 2017: Rheumatology and Therapy
https://www.readbyqxmd.com/read/29134606/intravenous-ferric-carboxymaltose-in-patients-with-type-2-diabetes-mellitus-and-iron-deficiency-clever-trial-study-design-and-protocol
#10
Christoph Schindler, Andreas L Birkenfeld, Markolf Hanefeld, Ulrike Schatz, Carsta Köhler, Martin Grüneberg, Diethelm Tschöpe, Matthias Blüher, Christoph Hasslacher, Stefan R Bornstein
INTRODUCTION: HbA1c is the gold standard for glycemic control in pre-diabetes and diabetes. However, its validity has been questioned, especially in the presence of imbalanced iron homeostasis. The CLEVER trial aims to evaluate the relationship between iron deficiency and HbA1c (a biomarker for the diagnosis and therapeutic monitoring of type 2 diabetes) in a randomized, placebo-controlled, multicenter clinical trial. METHODS: The CLEVER (intravenous ferric CarboxymaLtosE for improVement of mEtabolic parameters in type 2 diabetes patients with iRon deficiency) trial is a randomized, single-blind, proof-of-concept study with two treatment arms...
November 13, 2017: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/29118560/the-effectiveness-of-intravenous-iron-for-iron-deficiency-anemia-in-gastrointestinal-cancer-patients-a-retrospective-study
#11
Laurens Verhaeghe, Luk Bruyneel, Elisabeth Stragier, Marc Ferrante, Daan Dierickx, Hans Prenen
Background: Knowledge of the role of intravenous iron without the use of additional erythropoietic stimulating agents in anemic cancer patients is limited. This study evaluated the effect of ferric carboxymaltose (FCM) in a group of digestive oncology (DIO) patients and aimed to differentiate therapy response according to different types of iron deficiency (ID) anemia. Methods: In this retrospective study, we identified DIO patients who were receiving FCM and had eligible baseline and follow-up hemoglobin (Hb) levels that did not require red blood cell transfusion...
2017: Annals of Gastroenterology: Quarterly Publication of the Hellenic Society of Gastroenterology
https://www.readbyqxmd.com/read/29057687/safety-and-efficacy-of-intravenous-iron-administration-for-uterine-bleeding-or-postpartum-anaemia-a-narrative-review
#12
Angelos Daniilidis, Nikolaos Panteleris, Efthymia Vlachaki, Christian Breymann, Efstratios Assimakopoulos
The management of iron deficiency anaemia (IDA) consists of oral or intravenous administration of iron supplements. The aim of this narrative review is to summarise information regarding the treatment of IDA in women who have postpartum anaemia or uterine bleeding with intravenous (IV) or oral iron supplements. Fourteen randomised control studies comparing IV to oral iron treatment for IDA in 2913 women with uterine bleeding or postpartum haemorrhage are included. All reviewed studies suggest that IV iron administration is important in treating the IDA in such women and in improving their physical performance and quality of life...
October 23, 2017: Journal of Obstetrics and Gynaecology: the Journal of the Institute of Obstetrics and Gynaecology
https://www.readbyqxmd.com/read/29052292/intravenous-ferric-carboxymaltose-for-heart-failure-with-iron-deficiency
#13
EDITORIAL
Andrew J Stewart Coats
No abstract text is available yet for this article.
October 19, 2017: European Journal of Heart Failure
https://www.readbyqxmd.com/read/29033620/comparative-safety-of-intravenous-ferumoxytol-versus-ferric-carboxymaltose-for-the-treatment-of-iron-deficiency-anemia-rationale-and-study-design-of-a-randomized-double-blind-study-with-a-focus-on-acute-hypersensitivity-reactions
#14
N Franklin Adkinson, William E Strauss, Kristine Bernard, Robert F Kaper, Iain C Macdougall, Julie S Krop
BACKGROUND: Intravenous (IV) iron is often used to treat iron deficiency anemia in patients who are unable to tolerate or are inadequately managed with oral iron. However, IV iron treatment has been associated with acute hypersensitivity reactions. The comparative risk of adverse events (AEs) with IV iron preparations has been assessed by a few randomized controlled trials, which are most often limited by small patient numbers, which lack statistical power to identify differences in low-frequency AE such as hypersensitivity reactions...
2017: Journal of Blood Medicine
https://www.readbyqxmd.com/read/29032713/intravenous-iron-treatments-for-iron-deficiency-anemia-in-inflammatory-bowel-disease-a-budget-impact-analysis-of-iron-isomaltoside-1000-monofer-in-the-uk
#15
R F Pollock, G Muduma
Iron deficiency is the leading cause of anemia in patients with inflammatory bowel disease (IBD). Intravenous iron is the first-line treatment for clinically active IBD or previous oral iron intolerance. The aim of the present study was to develop a comparative model of iron deficiency and delivery for iron isomaltoside (IIM), ferric carboxymaltose (FCM), low molecular weight iron dextran (LMWID), and iron sucrose (IS) in the treatment of iron deficiency anemia associated with IBD. Areas covered: A model was developed to evaluate iron delivery characteristics, resource use and costs associated with IIM, FCM, LMWID and IS...
October 24, 2017: Expert Opinion on Drug Delivery
https://www.readbyqxmd.com/read/29016575/role-of-intravenous-ferric-carboxy-maltose-in-pregnant-women-with-iron-deficiency-anaemia
#16
Vineet Mishra, Khusaili Gandhi, Priyankur Roy, Shaheen Hokabaj, Kunur N Shah
BACKGROUND: Iron deficiency is a common nutritional deficiency amongst women of childbearing age. Peri-partum iron deficiency anaemia is associated with significant maternal, foetal and infant morbidity. Current options for treatment include oral iron, which can be ineffective and poorly tolerated, and red blood cell transfusions, which carry an inherent risk and should be avoided. Ferric carboxymaltose is a modern treatment option. The study was designed to assess the safety and efficacy of intravenous ferric carboxymaltose for correction of iron deficiency anaemia in pregnant women...
September 8, 2017: Journal of Nepal Health Research Council
https://www.readbyqxmd.com/read/28973244/ferric-carboxymaltose-to-treat-isovolemic-anemia-reply
#17
LETTER
Young-Woo Kim, Hannah Yang
No abstract text is available yet for this article.
October 3, 2017: JAMA: the Journal of the American Medical Association
https://www.readbyqxmd.com/read/28973241/ferric-carboxymaltose-to-treat-isovolemic-anemia
#18
LETTER
Zhang Yu, Tiangui Li
No abstract text is available yet for this article.
October 3, 2017: JAMA: the Journal of the American Medical Association
https://www.readbyqxmd.com/read/28940095/diagnosis-and-treatment-of-iron-deficiency-anaemia-in-pregnancy-and-postpartum
#19
C Breymann, C Honegger, I Hösli, D Surbek
Iron deficiency occurs frequently in pregnancy and can be diagnosed by serum ferritin-level measurement (threshold value < 30 μg/L). Screening for iron-deficiency anemia is recommended in every pregnant women, and should be done by serum ferritin-level screening in the first trimester and regular hemoglobin checks at least once per trimester. In the case of iron deficiency with or without anaemia in pregnancy, oral iron therapy should be given as first-line treatment. In the case of severe iron-deficiency anemia, intolerance of oral iron, lack of response to oral iron, or in the case of a clinical need for rapid and efficient treatment of anaemia (e...
December 2017: Archives of Gynecology and Obstetrics
https://www.readbyqxmd.com/read/28921558/safety-and-efficacy-of-intravenous-iron-polymaltose-iron-sucrose-and-ferric-carboxymaltose-in-pregnancy-a-systematic-review
#20
REVIEW
Alaa Qassim, Ben W Mol, Rosalie M Grivell, Luke E Grzeskowiak
BACKGROUND: Intravenous (IV) iron in pregnancy is useful where oral iron is not tolerated or a rapid replenishment of iron is required. AIMS: To review the literature on the efficacy and safety of different IV iron preparations in the management of antenatal iron-deficiency anaemia (IDA). MATERIALS AND METHODS: We searched MEDLINE, Embase and Scopus from inception to June 2016. Eligible studies were randomised controlled trials (RCTs) and observational studies, involving administration of IV iron (ferric carboxymaltose (FCM), iron polymaltose (IPM) or iron sucrose (IS)), regardless of comparator, to manage antenatal IDA...
September 18, 2017: Australian & New Zealand Journal of Obstetrics & Gynaecology
keyword
keyword
11331
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"